These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin. Di Stefano M; Corazza GR Chemotherapy; 2005; 51 Suppl 1():103-9. PubMed ID: 15855754 [TBL] [Abstract][Full Text] [Related]
25. Review article: the current pharmacological therapies for hepatic encephalopathy. Bass NM Aliment Pharmacol Ther; 2007 Feb; 25 Suppl 1():23-31. PubMed ID: 17295849 [TBL] [Abstract][Full Text] [Related]
26. Rifaximin (Xifaxan 550) for hepatic encephalopathy. Med Lett Drugs Ther; 2010 Nov; 52(1350):87. PubMed ID: 21045761 [No Abstract] [Full Text] [Related]
27. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Huang E; Esrailian E; Spiegel BM Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657 [TBL] [Abstract][Full Text] [Related]
28. Durability of rifaximin response in hepatic encephalopathy. Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586 [TBL] [Abstract][Full Text] [Related]
29. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837 [TBL] [Abstract][Full Text] [Related]
31. Infectious diarrhea in the aged: controlled clinical trial of rifaximin. Della Marchina M; Renzi G; Palazzini E Chemioterapia; 1988 Oct; 7(5):336-40. PubMed ID: 3066519 [TBL] [Abstract][Full Text] [Related]
32. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Lauritano EC; Gabrielli M; Lupascu A; Santoliquido A; Nucera G; Scarpellini E; Vincenti F; Cammarota G; Flore R; Pola P; Gasbarrini G; Gasbarrini A Aliment Pharmacol Ther; 2005 Jul; 22(1):31-5. PubMed ID: 15963077 [TBL] [Abstract][Full Text] [Related]
33. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Furnari M; Parodi A; Gemignani L; Giannini EG; Marenco S; Savarino E; Assandri L; Fazio V; Bonfanti D; Inferrera S; Savarino V Aliment Pharmacol Ther; 2010 Oct; 32(8):1000-6. PubMed ID: 20937045 [TBL] [Abstract][Full Text] [Related]
34. Intestinal bacterial overgrowth during chronic pancreatitis. Trespi E; Ferrieri A Curr Med Res Opin; 1999; 15(1):47-52. PubMed ID: 10216811 [TBL] [Abstract][Full Text] [Related]
35. Rifaximin: new therapeutic indication and future directions. Rivkin A; Gim S Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091 [TBL] [Abstract][Full Text] [Related]
36. Rifaximin for treatment of hepatic encephalopathy. Maclayton DO; Eaton-Maxwell A Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143 [TBL] [Abstract][Full Text] [Related]
37. Toxic epidermal necrolysis associated with rifaximin. Patel AS; Supan EM; Ali SN Am J Health Syst Pharm; 2013 May; 70(10):874-6. PubMed ID: 23640348 [TBL] [Abstract][Full Text] [Related]
38. Rifaximin is largely safe and well tolerated but caution is necessary when taken with statins. Cacciottolo TM; Kingdon A; Alexander GJ Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1765. PubMed ID: 24703862 [No Abstract] [Full Text] [Related]